Montelukast in Bronchiolitis Obliterans Syndrome

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Chronic rejection (or Bronchiolitis Obliterans syndrome-BOS) is a major cause of mortality and morbidity after lung transplantation. Because montelukast has been shown to be of some efficacy in a similar disease (Obliterative Bronchiolitis after bone marrow transplantation), the investigators would like to test if montelukast can indeed slow down the progression of chronic rejection after lung transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitaire Ziekenhuizen Leuven
• Collaborators: Katholieke Universiteit Leuven; KU Leuven
• Treatments: Montelukast

Criteria

Inclusion Criteria:

• Diagnosis of fBOS

• Signed informed consent

• Age at least 18 years old at moment of transplantation

• Able to take oral medication

Exclusion Criteria:

• Retransplantation

• Previous organ transplantation

• Multi organ transplantation